Coats disease with retinal neovascularization under subfoveal nodule: optical coherence tomography-angiography findings before and after ranibizumab treatment

Arq Bras Oftalmol. 2021 Jul-Aug;84(4):383-386. doi: 10.5935/0004-2749.20210062.

Abstract

We conducted retinal neovascularization under subfoveal fibrotic nodule for Coats disease by using optic coherence tomography-angiography before and after ranibizumab treatment. Our patient was an 8-year-old boy who was referred with suspicious left retinal mass. His visual acuity was 20/400 in the left eye and 20/20 in the right eye at the time of admission. Posterior segment evaluation of the left eye revealed telengiectatic vessels at the inferotemporal region of the peripheral retina with hard exudates around the optic disc and macula typical for Coats disease. His optic coherence tomography revealed a subfoveal fibrotic nodule after ranibizumab injections and laser photocoagulation treatment. The optic coherence tomography-angiography results revealed neovascularization under the subfoveal nodule at the superficial vascular complex layer. After 3 intravitreal ranibizumab injections, his neovascularization regressed on optic coherence tomography-angiography and his visual acuity improved. To the best of our knowledge, this is the first report demonstrating neovascularization under the subfoveal fibrotic nodule in Coats disease on the basis of comparative with the help of optic coherence tomography-angiography before and after the treatment.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Child
  • Choroidal Neovascularization* / drug therapy
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Ranibizumab / therapeutic use
  • Retinal Neovascularization* / diagnostic imaging
  • Retinal Neovascularization* / drug therapy
  • Retinal Telangiectasis* / complications
  • Retinal Telangiectasis* / diagnostic imaging
  • Retinal Telangiectasis* / drug therapy
  • Tomography, Optical Coherence

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab